Phd Candidate, Physicist


Maria-Argyro Karageorgou received her BSc in Physics (2009) from the University of Patras and her MSc in Biomedical Engineering (2012) from the University of Patras and the National Technical University of Athens. She is currently pursuing her doctorate at the Radiochemical Studies Laboratory of the Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety of NCSR “Demokritos”. As part of her PhD thesis entitled “Radiolabeled magnetic nanoparticles for dual-modality disease imaging”, she investigates the development of magnetic nanoparticles radiolabeled with positron-emitting and/or photon-emitting radionuclides, for potential application as dual-modality contrast agents in molecular imaging of different diseases. Dual-modality contrast agents, such as radiolabeled magnetic nanoparticles, are promising candidates for a number of imaging applications, since they combine the advantages of two different imaging modalities, namely single photon emission computed tomography (SPECT) or positron emission tomography (PET) with magnetic resonance imaging (MRI). The benefit of such a combination relates to the interpretation of the obtained imaging information in a more accurate way so that underlying diseases are reliably diagnosed at early stages. For the above scope, she utilizes X-ray diffraction, dynamic light scattering, optical and atomic force microscopy for the physico-chemical characterization of the dual-modality contrast agents and she performs in vitro and in vivo experiments on donated human blood and animal models, respectively, with the aim to assess both biocompatibility and biodistribution issues of these agents. Her PhD thesis will be defended at the Department of Physics of the National and Kapodistrian University of Athens.

Selected Grants

COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals

2020-2024 | European Cooperation in Science and Technology (COST)

The purpose of the COST Action CA19114 entitled "Network for Optimized Astatine-labeled Radiopharmaceuticals" (NOAR) is to create a network of scientists to investigate the production conditions of the α-particle emitter Astatine-211 (Astatine-211: 211At) and its application in Targeted A...


COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"

2018-2022 | European Cooperation in Science and Technology (COST)

The COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside" focuses on the development of nanosystems transporting anti-cancer drugs. The pan-European network of specialists from universities, research centers, clinical research organizations and companies is ...


Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer

2020-2021 | ΕΣΠΑ/Εκπαίδευση και Δια Βίου Μάθηση

The present research project is focused on the development of iron oxide nanoparticles (IONPs) radiolabeled with 68Ga, for dual-modality molecular imaging of prostate cancer with PET/MRI. These NPs are functionalized with adequate pharmacophores (peptides or peptidomimetic molecules) so a...

INRASTES - Official Web Site
Skip to content